General Information of Drug (ID: DM2KCIP)

Drug Name
GSK3179106 Drug Info
Synonyms
RET Kinase inhibitor 1; SCHEMBL16055027; CHEMBL3355009; IDXKJSSOUXWLDB-UHFFFAOYSA-N; CS-7799; HY-100459; 1627856-64-7; 2-(4-(4-ethoxy-6-oxo-1,6-dihydropyridin-3-yl)-2-fluorophenyl)-N-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)acetamide
Indication
Disease Entry ICD 11 Status REF
Inflammatory bowel disease DD72 Phase 1 [1]
Cross-matching ID
PubChem CID
78427026
CAS Number
CAS 1627856-64-7
TTD Drug ID
DM2KCIP

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug(s) Targeting Proto-oncogene c-Ret (RET)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Romiplostim DM3U7SZ Thrombocytopenia 3B64 Approved [2]
Regorafenib DMHSY1I Gastrointestinal stromal tumour 2B5B Approved [3]
Ponatinib DMYGJQO Acute lymphoblastic leukaemia 2A85 Approved [3]
Vandetanib DMRICNP Solid tumour/cancer 2A00-2F9Z Approved [4]
Selpercatinib DMZR15V Non-small-cell lung cancer 2C25.Y Approved [5]
Pralsetinib DMWU0I2 Non-small-cell lung cancer 2C25.Y Approved [6]
MGCD516 DM752PU Solid tumour/cancer 2A00-2F9Z Phase 2/3 [7]
CEP-32496 DMAO04B Solid tumour/cancer 2A00-2F9Z Phase 1/2 [8]
TPX-0046 DMIVE67 Solid tumour/cancer 2A00-2F9Z Phase 1/2 [9]
BOS172738 DM9L0D8 Solid tumour/cancer 2A00-2F9Z Phase 1 [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Proto-oncogene c-Ret (RET) TT4DXQT RET_HUMAN Inhibitor [1]

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Synthesis, structure-activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1482-96.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
7 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2185).
8 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9 Clinical pipeline report, company report or official report of Turning Point Therapeutics.
10 National Cancer Institute Drug Dictionary (drug name Zeteletinib).